All News

Janet Pope Tweet
Janetbirdope
Early RA is getting better over time periods but maybe just ACPA positive for sustained drug free remission. Counter intuitive. But still more in ACPA beg but less improvement Interesting. #ACR #ACR19 @RheumNow abstract 2871 https://t.co/JQJ90wxksi
Dr. Antoni Chan Tweet
synovialjoints
Treatment approach for skin disease in systemic sclerosis SSc from Hummers L. Polymerase 3 antibody predictive of skin progression and MMF benecial for treating SSc skin disease #ACR19 @RheumNow https://t.co/rdHOS9S23u
Mike Putman Tweet
EBRheum
#ACR19 Abst#2878 #ACRbest - Tildrakizumab (IL23i) RCT Good ACR20 (80% v 51%, NNT ~3) regardless of dose; great safety profile. Curiously high PLBO response, expectation bias? PASI75 phenomenal per usual (80% v 17% plbo, NNT 1-2) Need IL23/IL17/TNF comparative study! @RheumNow https://t.co/uEGvsD8KVb
Mike Putman Tweet
EBRheum
#ACR19 Guidelines for OA: my take home is this truly astonishing funnel plot Virtually zero small negative studies and dozens of small positive studies Clear trend toward NO effect w/more precision in trial Publication bias et al. in action!! @RheumNow https://t.co/65nKzghobz
Olga Petryna Tweet
DrPetryna
@RheumNow #acr19 abs2876 GODACT ph3 trial: glimumab+MTX improves clinical& MRI dactylitis scores better than MTX mono. mean MTX dose in the golimumab+ MTX group 16.3mg/wk & 19.2mg/wk in the MTX mono group . Also better DAS28,DAPSA,PASDAS& tNAPSI at wk 24 in golimumab group
Janet Pope Tweet
Janetbirdope
Practical tips for Raynauds in curbside consults. If Raynauds onsets at age less than 40 and no symptoms or signs of secondary causes such as CTD and normal nailfold capillaries likely no investigations are needed 5T118 #ACR #ACR19 #Scleroderma @RheumNow https://t.co/59gnI5ECNZ
Jonathan Hausmann MD Tweet
hausmannMD
”...too much attention to developing the memory and not enough to developing the mind.” William J. Mayo, 1933. Couldn't have said it better myself. Remains a challenge in #MedEd to this day. #ACR19 @RheumNow
Dr. John Cush Tweet
RheumNow
RheumNow's expanded coverage of the #ACR2019 annual meeting is sponsored in part by Novartis. All content chosen by RheumNow and its faculty.
Dr. Paul Sufka Tweet
psufka
#ACR19 Review Course — Update in RA Therapy 2019 — Dr. Michael Weinblatt. My notes in thread ⬇️⬇️⬇️
Janet Pope Tweet
Janetbirdope
Should we measure vit D in all pregnant women with SLE? As in general population low vitamin D increased miscarriage and preterm births. Weird as so did high vitamin D. Abstr 2531 #ACR #ACR19 @RheumNow #SLE #sle https://t.co/Mwb3WoCyBA
Dr Irwin Lim Tweet
_connectedcare
Size of M protein, type & abnormal free light chain protein ratio allows prognostication for MGUS #ACR19 @rheumnow 5T064
Kanika Monga, MD Tweet
DrKanikaMonga
What contributes to serious infections in RA? Higher inflammation and GC use, not bDMARD or tofacitinib use increased infectious risk Bella Mehta et al. RMD Open 2019 #ACR19 @RheumNow
Kanika Monga, MD Tweet
DrKanikaMonga
- Risk of bDMARD withdrawal higher for TNFi monotherapy compared w/ cs/bDMARD combination - If monotherapy necessary, etanercept should be preferred over infliximab and adalimumab Silvagni E et al. BMJ Open 2018 #ACR19 @RheumNow
Dr. John Cush Tweet
RheumNow
RheumNow's expanded coverage of the #ACR2019 annual meeting is sponsored in part by Sanofi Genzyme and Regeneron. All content chosen by RheumNow and its faculty.
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×